Stock comparison
ResMed
STERIS
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
STE
STERIS
Market cap
$21.26B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | STE | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 53C | RMD |
| Benjamin Graham | 75B | 68B | RMD |
| Philip Fisher | 75B | 58C | RMD |
| Peter Lynch | 58C | 52C | RMD |
| Joel Greenblatt | 47D | 35D | RMD |
| Charlie Munger | 69B | 42D | RMD |
| Terry Smith | 73B | 48D | RMD |
Side-by-side metrics
| Metric | RMD | STE |
|---|---|---|
| Market cap | $30.18B | $21.26B |
| P/E (TTM) | 19.6x | 25.3x |
| EV/EBIT | 17.1x | 17.7x |
| ROIC (TTM) | 19.63% | 8.51% |
| Gross margin | 61.69% | 44.25% |
| Net margin | 27.44% | 13.18% |
| Revenue CAGR 5y | 12.64% | 8.88% |
| EPS CAGR 5y | 30.73% | 33.45% |
| Debt / Equity | 0.1x | 0.0x |
| Dividend yield | 1.14% | 1.22% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- ROIC (TTM)19.63%vs 8.51%+57%
- Net margin27.44%vs 13.18%+52%
- Revenue CAGR 5y12.64%vs 8.88%+30%
- Market cap$30.18Bvs $21.26B+30%
STE leads on
- Debt / Equity0.0xvs 0.1x+87%
- EPS CAGR 5y33.45%vs 30.73%+8%
- Dividend yield1.22%vs 1.14%+6%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.